

Estimate change	↑
TP change	↑
Rating change	↔

CMP: INR2,199 TP: INR2,360 (+7%) Neutral

Strong execution drives margin to decade high

Competition and pipeline gestation to cap earnings trajectory

Bloomberg	LPC IN
Equity Shares (m)	457
M.Cap.(INRb)/(USDb)	1005 / 11.1
52-Week Range (INR)	2249 / 1774
1, 6, 12 Rel. Per (%)	2/7/-4
12M Avg Val (INR M)	2048

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	269.6	291.0	314.6
EBITDA	77.0	72.2	76.8
Adj. PAT	49.6	46.9	49.3
EBIT Margin (%)	23.9	20.4	20.1
Cons. Adj. EPS (INR)	109.1	103.1	108.4
EPS Gr. (%)	51.6	-5.5	5.2
BV/Sh. (INR)	499.5	599.7	705.2

Ratios

Net D:E	-0.1	-0.3	-0.4
RoE (%)	24.8	18.8	16.6
RoCE (%)	20.8	16.7	15.4
Payout (%)	2.7	2.8	2.7

Valuations

P/E (x)	20.2	21.3	20.3
EV/EBITDA (x)	11.4	11.6	10.3
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	5.5	5.2	5.6
EV/Sales (x)	3.3	2.9	2.5

Shareholding pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	46.9	46.9	47.0
DII	25.6	26.6	24.8
FII	21.5	20.5	22.0
Others	6.0	6.1	6.3

FII Includes depository receipts

- Lupin (LPC) posted a better-than-expected financial performance in 3QFY26, with 6%/16%/22% beat on revenues/EBITDA/PAT. Robust traction in US and other developed markets helped LPC sustain profitable growth momentum in 3Q.
- LPC delivered its highest-ever quarterly EBITDA margin in the past 10 years.
- Breaking its own record, it delivered the highest-ever quarterly US sales of USD350m in 3Q, led by the scale-up in recent launches.
- The company continued to outperform the India pharma market (IPM), with increased focus on chronic therapies, footprint expansion, and innovative product pipeline (13 launches in YTD FY26).
- Further, LPC is leveraging its portfolio in other developed markets and emerging markets to increase R&D productivity and capacity utilization.
- We raise our earnings estimates by 7%/4%/7% for FY26/FY27/FY28, factoring in a) higher sales from certain limited competition products, b) improved outlook for domestic formulation (DF) segment through product launches and increased marketing efforts, and c) superior traction in other developed/emerging markets. We value LPC at 22x 12M forward earnings to arrive at a TP of INR2,360.
- We believe that FY26 will be the second consecutive year of strong earnings growth; however, competition in certain products and some gestation period for commercialization of complex product pipeline in inhalation, injectables and biosimilar space could limit LPC's earnings growth over FY26-28. Maintain Neutral on the stock.

Product mix, operating leverage drive robust earnings growth

- 3Q revenue grew 25.9% YoY to INR71.7b (our est. INR67.6b).
- Gross margin (GM) expanded 400bp YoY to 73.8%.
- EBITDA margin expanded 660bp YoY to 30.8% (our est: 28.1%), largely due to better GM.
- As a result, EBITDA grew 60.5% YoY to INR22.1b (vs our est: INR19.0b).
- Adj. PAT grew 71.4% YoY to INR14.7b (our est: INR12.0b).
- For 9MFY26, revenue/EBITDA/PAT grew 22%/51%/56% YoY.

Broad-based growth across key geographies

- US sales grew 54% YoY to INR31.1b (up 46% YoY in CC to USD350m; 44% of sales).
- DF sales grew 5.6% YoY to INR20.4b (29% of sales). Rx business rose 10.9% YoY.
- Other developed market sales grew 10.8% YoY to INR8b (11% of sales).
- Emerging market sales grew 42.4% YoY to INR 9.2b (13% of sales).
- API sales decreased 24.1% YoY to INR2.2b (3% of sales).

Highlights from the management commentary

- LPC has reiterated its EBITDA margin guidance of 24-25% in FY27.
- The company would have a licensing outgo of more than USD75 per unit licensing fee with respect to Mirabegron. Still LPC believes the profitability to remain healthy in this product.
- It added 600 MRs for Rx market in India.
- LPC has created a separate division comprising 200 MRs for the semaglutide opportunity to reach out to the doctor pool comprising diabetologist, cardiologist, and gastroenterologist.
- LPC expects to sustain US sales at USD1b over the next couple of years.

Consolidated - Quarterly earnings model

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	% Var
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	
Net Sales	56,003	55,427	56,927	56,671	62,684	70,475	71,675	64,803	2,25,028	2,69,637	67,614	6.0
YoY Change (%)	21.5	10.0	9.5	14.2	11.9	27.1	25.9	14.3	13.6	19.8	18.8	
Total Expenditure	42,389	43,059	43,162	43,750	46,269	49,099	49,580	47,695	1,72,361	1,92,643	48,614	
EBITDA	13,614	12,368	13,765	12,921	16,415	21,376	22,095	17,108	52,668	76,994	18,999	16.3
YoY Change (%)	109.0	34.0	34.7	29.6	20.6	72.8	60.5	32.4	46.6	46.2	38.0	
Margins (%)	24.3	22.3	24.2	22.8	26.2	30.3	30.8	26.4	23.4	28.6	28.1	
Depreciation	2,477	2,569	2,715	3,932	2,990	3,168	3,130	3,291	11,693	12,578	3,434	
EBIT	11,137	9,799	11,050	8,989	13,425	18,208	18,965	13,817	40,975	64,416	15,566	
YoY Change (%)	167.3	45.1	44.5	21.3	20.5	85.8	71.6	53.7	57.7	57.2	40.9	
Margins (%)	19.9	17.7	19.4	15.9	21.4	25.8	26.5	21.3	18.2	23.9	23.0	
Interest	680	709	669	891	918	1,076	1,150	224	2,949	3,367	820	
Other Income	678	423	537	570	790	900	1,147	-387	2,207	2,450	620	
EO Exp/(Inc)	1,204	-1,036	956	-291	-859	-2,037	3,742	0	834	846	0	
PBT	9,930	10,549	9,963	8,958	14,156	20,070	15,220	13,206	39,401	62,654	15,366	
Tax	1,875	1,954	2,124	1,135	1,941	5,221	3,415	2,932	7,087	13,509	3,304	
Rate (%)	18.9	18.5	21.3	12.7	13.7	26.0	22.4	22.2	18.0	21.6	21.5	
Minority Interest	-42	-69	-37	-99	-24	-69	-50	-72	-246	-215	-70	
Reported PAT	8,013	8,526	7,802	7,726	12,191	14,779	11,756	10,203	32,067	48,928	11,992	
Adj PAT	8,990	7,682	8,554	7,472	11,450	13,272	14,658	10,203	32,698	49,582	11,992	22.2
YoY Change (%)	214.9	55.5	42.6	47.0	27.4	72.8	71.4	36.5	73.2	51.6	40.2	
Margins (%)	16.1	13.9	15.0	13.2	18.3	18.8	20.5	15.7	14.5	18.4	17.7	
EPS	20	17	19	16	25	29	32	22	72	109	26	22.2




Highlights from the management interaction

- Beyond the current commercial product, US growth drivers are injectables (Dalbavancin/iron sucrose and smaller profitable opportunities), biosimilars (Pegfilgrastim, renibizumab, aflibercept with potential combined sales of USD100m), and respiratory products.
- The company has 40% generic market share in mirabegron.
- LPC has ~67% of Rx portfolio, driven by chronic therapies (vs. 65% QoQ).
- It has implemented AI in marketing/sales and has been working with consultants to not only collect required data but also optimize the field force productivity.
- US sales was driven by niche launches, higher volumes from base products and seasonal tailwinds.
- Brazil grew 99% YoY (local currency), driven by dapagliflozin commercialization.


Key exhibits

Exhibit 1: US sales increased 54% YoY in 3QFY26



Source: MOFSL, Company

Exhibit 2: DF sales increased 5.6% YoY in 3QFY26



Source: MOFSL, Company

Structural growth phase led by US complex expansion and domestic chronic strength

US – Business scaling up on complex and biosimilar expansion

- LPC sustained strong momentum with 35% YoY growth in 9MFY26, reaching revenue of USD947m.
- The US business recorded its highest-ever quarterly sales of USD350m in 3QFY26, growing 46% YoY and 11% QoQ, driven by Tolvaptan exclusivity gains, Mirabegron contribution, and steady growth in the base portfolio.
- During the quarter, LPC received one ANDA approval and launched three products, taking its total US marketed generics portfolio to 149 products and further diversifying revenue streams.
- Biosimilars represent the next growth engine, with Pegfilgrastim launch imminent and pipeline assets including Ranibizumab, on-body Pegfilgrastim, Aflibercept, and Etanercept slated for commercialization over FY27-30.
- The institutional and injectable portfolio continues to expand with launches such as Glucagon, Liraglutide, and Risperdal Consta, which are expected to scale meaningfully over the next two to three years.
- The 505(b)(2) pipeline may begin contributing from FY27, adding differentiated products beyond traditional generics and supporting margin expansion.
- Management aims to double the share of complex products in US revenue mix over the next few years, strengthening revenue durability and earnings visibility.
- LPC maintains a healthy pipeline, comprising 45+ injectables, 20+ inhalation assets, 52 FTFs including 22 exclusive FTFs, and 10-15 planned ANDA filings in FY26, including two 505(b)(2) filings, providing multi-year launch visibility.
- We build in an 11% sales CAGR for the US segment over FY25-28, reaching USD1.3b, driven by scaling biosimilars, expanding complex injectables and inhalation launches, leveraging 505(b)(2) assets, and selectively strengthening the specialty portfolio.

DF – Chronic mix and innovation drive structural growth

- LPC delivered a steady domestic performance with revenue growth of 6% YoY to INR62b in 9MFY26 despite the loss of exclusivity in key in-licensed anti-diabetes


products and lower local tender sales. Growth was supported by resilient underlying prescription momentum.

- The core prescription business grew 10.9% in 3QFY26 and 9.4% in 9MFY26, broadly in line with IPM growth.
- Chronic therapies grew 13% in 9MFY26 vs. IPM growth of 12%, with the chronic mix increasing to ~67% in 3QFY26 from ~64% in FY25, strengthening the structural revenue base.
- Key therapeutic segments outperformed the market in 9MFY26, with Cardiology growing at 1.3x, Respiratory at 1.6x, GI at 1.6x, and Pain at 1.2x of their respective IPM growth rates.
- Volume growth of 5.6% in 9MFY26 reflects healthy prescription traction, supported by an expanded sales force of ~11,400, including ~8,900 MRs.
- LPC launched three brands in 3Q and 13 products in 9MFY26 while establishing a dedicated obesity division to capture emerging GLP-1 opportunities.
- Expansion initiatives include strengthening gastro and respiratory task forces, scaling extra-urban presence, and building partnerships across e-commerce, organized retail, and institutional channels.
- We expect a 9% sales CAGR in the DF segment over FY25-28, reaching INR97.4b, driven by increasing chronic mix toward ~70%, scaling up obesity and GLP-1 launches, executing a robust innovation pipeline, and expanding footprint across therapies and channels.

Maintain Neutral

- We raise our earnings estimates by 7%/4%/7% for FY26/FY27/FY28, factoring in a) higher sales from certain limited competition products, b) improved outlook for DF segment through product launches and increased marketing efforts, and c) superior traction in other developed/emerging markets. We value LPC at 22x 12M forward earnings to arrive at a TP of INR2,360.
- We believe that FY26 will be the second consecutive year of strong earnings growth; however, competition in certain products and some gestation period for commercialization of complex product pipeline in inhalation, injectables and biosimilar space could cap LPC's earnings trajectory over FY26-28. Maintain Neutral on the stock.

Exhibit 3: P/E chart



Story in charts

Exhibit 4: Revenue mix in 3QFY26




Exhibit 5: Expect 12% sales CAGR over FY25-28




Exhibit 6: R&D to be in range of 7.5%-8.5%




Exhibit 7: EBITDA margin to be in range of 24-25%




Exhibit 8: Expect EPS to register a 15% CAGR over FY25-28





Exhibit 9: 92 ANDAs – pending approval



Source: MOFSL, Company

Financials and valuations

Income Statement

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Net Sales	1,60,321	1,66,417	1,98,054	2,25,029	2,69,637	2,90,970	3,14,628
Change (%)	6.2	3.8	19.0	13.6	19.8	7.9	8.1
EBITDA	19,968	17,582	35,932	52,668	76,993	72,161	76,769
Margin (%)	12.5	10.6	18.1	23.4	28.6	24.8	24.4
Depreciation	8,220	8,807	9,956	11,693	12,578	12,891	13,478
EBIT	11,748	8,775	25,977	40,975	64,415	59,270	63,291
Int. and Finance Charges	1,428	2,743	3,116	2,949	3,367	2,971	2,777
Other Income - Rec.	1,504	757	1,218	2,207	2,450	2,550	2,650
PBT before EO item	11,824	6,790	24,079	40,234	63,498	58,849	63,164
EO Expense/(Income)	25,550	-375	-147	834	846	0	0
PBT after EO item	-13,726	7,165	24,227	39,400	62,652	58,849	63,164
Tax	1,372	2,688	4,867	7,087	13,509	11,770	13,580
Tax Rate (%)	-10.0	37.5	20.1	18.0	21.6	20.0	21.5
Less: Minority Interest	-183	-176	-211	-246	-215	-220	-310
Reported PAT	-15,280	4,301	19,149	32,066	48,928	46,859	49,274
PAT Adj for EO items	8,699	3,915	18,875	32,698	49,582	46,859	49,274
Change (%)	-26.2	-55.0	382.1	73.2	51.6	-5.5	5.2
Margin (%)	5.4	2.4	9.5	14.5	18.4	16.1	15.7

Consolidated Balance Sheet

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	909	910	909	913	909	909	909
Total Reserves	1,20,624	1,23,695	1,41,992	1,71,122	2,26,114	2,71,643	3,19,588
Net Worth	1,21,533	1,24,605	1,42,901	1,72,035	2,27,023	2,72,552	3,20,497
Minority Interest	687	783	831	909	1,124	1,344	1,654
Deferred liabilities	711	738	-567	-6,053	-3,327	-3,327	-3,327
Secured Loan	6,147	4,153	3,115	20,820	20,570	18,070	15,070
Unsecured Loan	37,023	42,165	26,699	34,173	29,104	25,104	21,104
Total Loans	43,170	46,318	29,814	54,993	49,675	43,175	36,175
Capital Employed	1,66,101	1,72,444	1,72,979	2,21,884	2,74,494	3,13,744	3,54,998
Gross Block	95,368	1,05,127	1,17,618	1,31,807	1,37,084	1,43,147	1,49,854
Less: Accum. Deprn.	49,870	58,677	68,632	80,325	92,903	1,05,793	1,19,271
Net Fixed Assets	45,498	46,450	48,986	51,482	44,181	37,354	30,583
Capital WIP	8,475	8,948	5,957	3,555	5,127	5,914	6,307
Investments	9,000	5,169	10,747	13,840	13,840	13,840	13,840
Goodwill & Intangibles	31,306	40,534	41,566	47,323	47,323	47,323	47,323
Curr. Assets	1,22,236	1,26,861	1,29,656	1,69,796	2,28,612	2,87,586	3,42,888
Inventory	46,307	44,918	49,539	54,764	54,354	69,407	78,429
Account Receivables	42,619	44,807	46,920	54,971	67,883	75,582	82,671
Cash and Bank Balance	10,981	12,931	12,025	31,423	77,690	1,13,858	1,52,999
Others	22,328	24,205	21,171	28,638	28,686	28,739	28,789
Curr. Liability & Prov.	50,414	55,519	63,931	64,111	64,589	78,272	85,941
Account Payables	42,254	46,937	54,928	57,019	57,496	71,179	78,849
Provisions	8,160	8,581	9,003	7,093	7,093	7,093	7,093
Net Current Assets	71,822	71,342	65,725	1,05,685	1,64,024	2,09,314	2,56,946
Appl. of Funds	1,66,101	1,72,444	1,72,979	2,21,884	2,74,494	3,13,744	3,54,998

E: MOSL Estimates

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
EPS	19.1	8.6	41.5	71.9	109.1	103.1	108.4
Cash EPS	37.2	28.0	63.4	97.2	136.8	131.5	138.1
BV/Share	267.4	273.9	314.4	376.8	499.5	599.7	705.2
DPS	9.0	2.0	2.5	2.5	2.5	2.5	2.5
Payout (%)	-31.3	24.7	6.9	4.1	2.7	2.8	2.7
Valuation (x)							
P/E	114.9	255.3	53.0	30.6	20.2	21.3	20.3
Cash P/E	59.1	78.7	34.7	22.6	16.1	16.7	15.9
P/BV	8.2	8.0	7.0	5.8	4.4	3.7	3.1
EV/Sales	5.8	5.6	4.7	4.1	3.6	3.2	2.8
EV/EBITDA	46.9	53.4	25.7	17.6	11.4	12.9	11.6
Return Ratios (%)							
RoE	6.7	3.2	14.1	20.8	24.8	18.8	16.6
RoCE	8.6	3.5	12.6	17.7	20.8	16.7	15.4
RoIC	9.8	3.9	14.3	21.2	28.8	26.5	27.5
Working Capital Ratios							
Asset Turnover (x)	1.0	1.0	1.1	1.0	1.0	0.9	0.9
Fixed Asset Turnover (x)	3.6	3.6	4.2	4.5	5.6	7.1	9.3
Debtor (Days)	97	98	86	89	92	95	96
Creditor (Days)	129	136	163	158	156	159	155
Inventory (Days)	105	99	91	89	74	87	91
Leverage Ratio							
Current Ratio	2.4	2.3	2.0	2.6	3.5	3.7	4.0
Interest Cover Ratio	8.2	3.2	8.3	13.9	19.1	19.9	22.8
Debt/Equity (x)	0.3	0.3	0.1	0.1	-0.1	-0.3	-0.4

Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
PBT Before EO items	-13,722	7,165	24,223	40,150	76,993	72,161	76,769
Int./Dividends Recd.	468	2,422	2,280	1,589	2,450	2,550	2,650
Direct Taxes Paid	469	-2,432	-3,261	-9,060	-10,783	-11,770	-13,580
(Inc)/Dec in WC	-150	3,265	855	-14,105	-12,073	-9,122	-8,491
CF from Operations	-12,936	10,420	24,098	18,573	56,588	53,819	57,348
Others	16,609	8,552	12,386	11,426	2	2	2
EO expense	0	0	0	0	846	0	0
CF from Op. incl EO Exp.	3,673	18,972	36,484	29,999	55,743	53,821	57,350
(inc)/dec in FA	-8,980	-14,611	-9,166	-16,531	-6,850	-6,850	-7,100
Free Cash Flow	-21,916	-4,191	14,931	2,042	49,738	46,969	50,248
(Pur)/Sale of Inv.	15,891	3,958	-5,374	-324	0	0	0
Others	6,011	-2,214	-2,582	-24,864	0	0	0
CF from Investments	12,922	-12,868	-17,122	-41,719	-6,850	-6,850	-7,100
Change in Net Worth	161	19	146	399	7,504	120	210
Inc/(Dec) in Debt	-11,693	700	-17,331	24,277	-5,319	-6,500	-7,000
Interest Paid	-1,240	-2,267	-2,829	-2,295	-3,367	-2,971	-2,777
Dividend Paid	-2,951	-1,825	-1,828	-3,653	-1,329	-1,329	-1,329
CF from Fin. Activity	-15,723	-3,373	-21,842	17,319	-2,627	-10,803	-11,109
Inc/Dec of Cash	872	2,732	-2,481	5,599	46,267	36,168	39,141
Add: Beginning Balance	9,262	9,913	12,317	9,836	15,436	61,702	97,870
Cash/Cash Eq.	10,134	12,645	9,836	15,436	61,702	97,870	1,37,011
Forex/Bank	-221	-328	0	15,988	15,988	15,988	15,988
Closing Balance	9,913	12,317	9,836	31,423	77,690	1,13,858	1,52,999

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Lupin
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and

interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motalal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motalal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore. Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motalal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motalal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motalal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motalal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motalal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.